Intended for patients who have been prescribed Semglee^®. This has been fully written and funded by Biosimilar Collaborations Ireland Limited, who are the marketing authorisation holder for Semglee^® (insulin glargine). Always refer to the patient information leaflet supplied with the medicine for detailed information or speak to your healthcare team.

▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See https://yellowcard.mhra.gov.uk/ for how to report side effects.

Reporting of side effects: If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk/. By reporting side effects, you can help provide more information on the safety of this medicine.